PROMEGA UK LIMITED

Financial Health Assessment: PROMEGA UK LIMITED

1. Financial Health Score: A- (Provisional) I am assigning a provisional score of A- because, while the patient exhibits excellent structural and compliance health, the specific quantitative "blood work" (the detailed financial figures from the annual accounts) was not provided in this dataset. Based on the available qualitative metrics—corporate longevity, regulatory compliance, and the strength of its parent company—the business shows no symptoms of distress. A full A+ grade would require confirming healthy liquidity and profitability through the actual filed financial statements.

2. Key Vital Signs * Corporate Longevity (Pulse): Incorporated in 1989, this business has a 35-year track record of survival. In corporate medicine, surviving multiple economic cycles indicates a robust constitution and an adaptable business model. The pulse is strong and steady. * Regulatory Compliance (Blood Pressure): Filing deadlines are the blood pressure of corporate health. Overdue accounts or confirmation statements are early warning signs of administrative distress or insolvency. Promega UK Limited has a clean bill of health here: its accounts are up to date (not overdue), and it files full accounts rather than abbreviated ones, demonstrating transparency and administrative wellness. * Ownership & Backing (Immune System): The PSC (People with Significant Control) register reveals that Promega Corporation (the US-based global parent) owns more than 75% of the shares. This acts as a powerful corporate immune system; the UK subsidiary has the financial backing of a worldwide leader in life sciences, significantly reducing the risk of sudden liquidity crises. * Leadership Stability (Neurological Function): The board includes William Alderman Linton (the American founder of the global Promega empire) and a dedicated UK Financial Controller. This indicates that the UK entity is firmly integrated into the parent company's strategic nervous system, with direct oversight from global leadership.

3. Symptoms Analysis & Diagnosis * Symptoms Analysis: There are absolutely no symptoms of distress. The company is actively trading, its status is clean, and it has no history of disqualifications against its directors. The change of name from Paystep Limited to Promega Limited in 1989, and then to Promega UK Limited in 1996, shows a healthy evolution from a shell entity into a fully integrated local arm of a global brand. * Diagnosis: The patient is a healthy, mature subsidiary operating in the specialized life sciences and biotechnology sector (SIC 74909). Because it is heavily anchored by its US parent, it does not suffer from the typical "lonely SME" vulnerabilities. However, as with any subsidiary, its internal financial health is deeply intertwined with the parent company's strategy. If the parent company catches a cold, the UK subsidiary might sneeze—meaning any diagnosis must acknowledge that its risk profile is largely tied to the global Promega Corporation.

4. Prognosis & Recommendations * Prognosis: The future outlook is highly positive. Operating as the UK arm of a global biotech leader provides structural resilience. As long as the life sciences sector continues to see demand for molecular biology and biochemistry products, this entity is well-positioned for steady, supported operations. * Recommendations: 1. Complete the Physical: To elevate this from a provisional to a definitive health grade, the actual balance sheet and profit & loss figures must be examined. I recommend reviewing the next set of filed accounts to check the "cholesterol" levels—specifically, whether the UK entity is carrying excessive intercompany debt (a common symptom in global subsidiaries) or maintaining healthy retained profits. 2. Monitor Intercompany Vital Signs: Because it is wholly owned by a US corporation, keep a close eye on intercompany balances. High levels of intercompany payable can sometimes indicate that the UK entity is financing the parent's cash flow, which is a symptom that requires management attention.